^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lenvima (lenvatinib)

    i
    Other names: E7080, E-7080, E 7080, ER 20349200, ER-203492-00, MK-7902, ER20349200, ER-20349200, MK7902, MK 7902
    Company:
    Eisai, Knight Therap, Merck (MSD)
    Drug class:
    c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist
    Related drugs:
    1d
    Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma. (PubMed, Exp Mol Med)
    Furthermore, the OST inhibitor NGI-1 and NGI-1-loaded nanoparticles exerted potent antitumor effects and further augmented the efficacy of lenvatinib and immunotherapy. These findings highlight DDOST as a promising therapeutic target to improve treatment outcomes in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Lenvima (lenvatinib)
    1d
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. (PubMed, PLoS One)
    In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.
    Retrospective data • Journal • Real-world evidence
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
    2d
    KEYMAKER-U06 substudy 06A: A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) (clinicaltrials.gov)
    P1/2, N=90, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • irinotecan • MK-4830 • favezelimab/pembrolizumab (MK-4280A)
    2d
    Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jun 2028 --> Aug 2025 | Trial completion date: Dec 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    3d
    Prolonged Survival in Anaplastic Thyroid Cancer: Insights From Multi-Modal Treatment. (PubMed, Asia Pac J Clin Oncol)
    This case series highlights promising outcomes with systemic treatment options in ATC, but the analysis is limited by a small sample size, emphasising the need for further research and collaboration to improve clinical outcomes.
    Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Lenvima (lenvatinib)
    4d
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Tongji Hospital
    New P1/2 trial
    |
    5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin
    4d
    Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=116, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • paclitaxel • Lenvima (lenvatinib) • Enshuxing (enlonstobart)
    4d
    PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial. (PubMed, Nat Commun)
    Further, we performed a post-hoc exploratory analysis and developed an XGBoost model (scPro-X) using scRNA-seq data from pre-treatment tumor samples to predict 12-week ORR identified CD4_Tfh_CXCL13 and CD8_Tex_CTLA4 as potential biomarkers predictive of response. These findings demonstrate that IBI318 plus lenvatinib exhibit promising clinical activity and a manageable safety profile in patients with advanced NSCLC.
    P2 data • Preclinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    4d
    CLEC4G Reverses Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing PD-1 Expression via the Wnt/β-Catenin Pathway. (PubMed, Int J Genomics)
    Silencing CLEC4G could reverse the effect of LiCl on PLC/PRF/5-R. CLEC4G modulates the PD-1 expression of HCC cells through the Wnt/β-catenin pathway, thereby reversing the resistance to Lenva.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    Lenvima (lenvatinib)
    8d
    Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape. (PubMed, Front Immunol)
    Advancements in single-cell analysis and spatial transcriptomics are anticipated to unveil actionable molecular patterns and support the development of individualized strategies to interrupt immune evasion and therapeutic resistance in EC. These advances offer promise for personalized immunotherapy approaches that could significantly improve outcomes in endometrial cancer patients.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    8d
    Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    CS1003-305: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=534, Active, not recruiting, CStone Pharmaceuticals | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    Lenvima (lenvatinib) • nofazinlimab (CS1003)